[开放获取]    脓疱型银屑病诊疗中国专家共识（2026版）

doi:10.35541/cjd.20250488

Abstract

Abstract: 【Abstract】 Pustular psoriasis is a special type of psoriasis, characterized by aseptic pustules on an erythematous base. Its etiology involves multiple factors such as heredity, immunity, and infection. Pustular psoriasis can be classified into 2 subtypes: localized and generalized pustular psoriasis. Localized pustular psoriasis is mainly managed with topical therapy, and patients with poor response to topical therapy can be treated with systemic and physical therapy; generalized pustular psoriasis is usually treated with systemic therapy, which can be combined with topical and physical therapy. Based on the latest Chinese and international guidelines and the “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022）”, and combined with the current status of diagnosis and treatment of pustular psoriasis in China, the expert committee developed this 2026 consensus, focusing on the clinical manifestations and classification, diagnostic workup, diagnostic criteria, and treatment of pustular psoriasis, with the aim of further establishing standardized clinical management protocols.

Key words: Psoriasis, Diagnosis, Therapy, Pustular psoriasis, Expert consensus

Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition）[J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.doi:10.35541/cjd.20250488

References ［74］

［1］	Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis［J］. Expert Rev Clin Immunol, 2019,15（9）:907⁃919. DOI: 10.1080/1744666X.2019.1648209.
［2］	张芊, 冯菁楠, 郭金竹, 等. 我国城镇掌跖脓疱病的流行病学特征和经济负担分析［J］. 中华预防医学杂志, 2024,58（5）:642⁃648. DOI: 10.3760/cma.j.cn112150⁃20230814⁃00089.
［3］	Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background［J］. Acta Derm Venereol, 1996,76（1）:68⁃71. DOI: 10.2340/00015555766871.
［4］	Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis （Zumbusch）: a French epidemiological survey［J］. Eur J Dermatol, 2006,16（6）:669⁃673.
［5］	Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in Asia? A population⁃based study using claim data in China and a systematic review［J］. Dermatology, 2023,239（2）:195⁃205. DOI: 10.1159/000528850.
［6］	《脓疱型银屑病诊疗中国专家共识（2022版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）［J］. 中华皮肤科杂志, 2022,55（3）:187⁃195. DOI: 10.35541/cjd.20210698.
［7］	Ayala⁃Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases［J］. Psoriasis （Auckl）, 2016,6:7⁃32. DOI: 10.2147/PTT.S64950.
［8］	Choon SE, Foley PA, Asawanonda P, et al. Asia⁃Pacific consensus recommendations on the management of generalized pustular psoriasis［J］. J Dermatol, 2024,51（12）:1579⁃1595. DOI: 10.1111/1346⁃8138.17471.
［9］	Sugiura K. Role of interleukin 36 in generalised pustular psoriasis and beyond［J］. Dermatol Ther （Heidelb）, 2022,12（2）:315⁃328. DOI: 10.1007/s13555⁃021⁃00677⁃8.
［10］	朱腾, 晋红中. 泛发性脓疱型银屑病的致病易感基因［J］. 协和医学杂志, 2016,7（6）:445⁃449. DOI: 10.3969/j.issn.1674⁃9081.2016.06.009.
［11］	Li X, Chen M, Fu X, et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris［J］. J Dermatol Sci, 2014,76（2）:132⁃138. DOI: 10.1016/j.jdermsci.2014.08.007.
［12］	Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin⁃36 signalling in plaque psoriasis and pustular psoriasis［J］. Acta Derm Venereol, 2018,98（1）:5⁃13. DOI: 10.2340/00015555⁃2808.
［13］	Körber A, Mössner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis［J］. J Invest Dermatol, 2013,133（11）:2634⁃2637. DOI: 10.1038/jid.2013.214.
［14］	Fu F, Sun Y, Zhao Q, et al. Rare CARD14 missense variants associated with palmoplantar pustulosis （PPP） in the Chinese Han population［J］. Eur J Dermatol, 2019,29（1）:99⁃100. DOI: 10.1684/ejd.2018.3457.
［15］	Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1792⁃1799. DOI: 10.1111/jdv. 14386.
［16］	Johnston A, Xing X, Wolterink L, et al. IL⁃1 and IL⁃36 are dominant cytokines in generalized pustular psoriasis［J］. J Allergy Clin Immunol, 2017,140（1）:109⁃120. DOI: 10.1016/j.jaci.2016.08.056.
［17］	Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis⁃associated IL⁃17A induces and cooperates with IL⁃36 cytokines to control keratinocyte differentiation and function［J］. Sci Rep, 2017,7（1）:15631. DOI: 10.1038/s41598⁃017⁃15892⁃7.
［18］	Arakawa A, Vollmer S, Besgen P, et al. Unopposed IL⁃36 activity promotes clonal CD4+ T⁃cell responses with IL⁃17A production in generalized pustular psoriasis［J］. J Invest Dermatol, 2018,138（6）:1338⁃1347. DOI: 10.1016/j.jid.2017. 12.024.
［19］	Brunasso A, Massone C. Recent advances in palmoplantar pustulosis［J］. Fac Rev, 2021,10:62. DOI: 10.12703/r/10⁃62.
［20］	Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis ⁃ a model disease for specific targeted immunotherapy, systematic review［J］. Exp Dermatol, 2018,27（10）:1067⁃1077. DOI: 10.1111/exd.13699.
［21］	Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism［J］. J Dermatol Sci, 2020,98（1）:13⁃19. DOI: 10.1016/j.jdermsci.2020. 03.003.
［22］	秦万章, 顾军, 王刚等. 银屑病学［M］. 南京: 江苏凤凰科学技术出版社, 2020:293⁃304.
［23］	Barker JN, Casanova E, Choon SE, et al. Global Delphi consensus on treatment goals for generalized pustular psoriasis［J］. Br J Dermatol, 2025,192（4）:706⁃716. DOI: 10.1093/bjd/ljae491.
［24］	Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. DOI: 10.1111/1346⁃8138.14523.
［25］	Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:737⁃752. DOI: 10.1111/jdv.18851.
［26］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. DOI: 10.35541/cjd.20190847.
［27］	Rivera⁃Díaz R, Daudén E, Carrascosa JM, et al. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment［J］. Dermatol Ther （Heidelb）, 2023,13（3）:673⁃688. DOI: 10.1007/s13555⁃022⁃00881⁃0.
［28］	Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the international psoriasis council［J］. JAMA Dermatol, 2024,160（7）:758⁃768. DOI: 10.1001/jamadermatol.2024.0915.
［29］	Sugiura K, Nakasuka A, Kono H, et al. Impetigo herpetiformis with IL36RN mutations in a Chinese patient: a founder haplotype of c.115+6T>C in East Asia［J］. J Dermatol Sci, 2015,79（3）:319⁃320. DOI: 10.1016/j.jdermsci.2015.06.003.
［30］	Sugiura K, Oiso N, Iinuma S, et al. IL36RN mutations underlie impetigo herpetiformis［J］. J Invest Dermatol, 2014,134（9）:2472⁃2474. DOI: 10.1038/jid.2014.177.
［31］	中国医师协会皮肤科医师分会儿童学组, 中华医学会皮肤性病学分会银屑病学组. 儿童脓疱型银屑病诊疗中国专家共识（2025版）［J］. 中华皮肤科杂志, 2025,58（4）:297⁃306. DOI: 10.35541/cjd.20240714.
［32］	Owczarczyk⁃Saczonek A, Znajewska⁃Pander A, Owczarek W, et al. Clinicopathologic retrospective analysis of annular pustular psoriasis［J］. Acta Dermatovenerol Alp Pannonica Adriat, 2018,27（4）:215⁃219.
［33］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. DOI: 10.35541/cjd.20220839.
［34］	Duffin KC, Bachelez H, Mease PJ, et al. Pustular psoriasis and associated musculoskeletal disorders［J］. J Rheumatol Suppl, 2021,97:34⁃38. DOI: 10.3899/jrheum.201673.
［35］	Armstrong AW, Elston CA, Elewski BE, et al. Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2024,90（4）:727⁃730. DOI: 10.1016/j.jaad.2023.09.080.
［36］	Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes［J］. J Allergy Clin Immunol, 2019,143（3）:1021⁃1026. DOI: 10.1016/j.jaci. 2018.06.038.
［37］	Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases［J］. Arch Dermatol, 1991,127（9）:1339⁃1345.
［38］	Kishimoto M, Taniguchi Y, Tsuji S, et al. SAPHO syndrome and pustulotic arthro⁃osteitis［J］. Mod Rheumatol, 2022,32（4）:665⁃674. DOI: 10.1093/mr/roab103.
［39］	Burden AD, Bachelez H, Choon SE, et al. The Generalized Pustular Psoriasis Physician Global Assessment （GPPGA） score: online assessment and validation study of a specific measure of GPP disease activity［J］. Br J Dermatol, 2023,189（1）:138⁃140. DOI: 10.1093/bjd/ljad071.
［40］	Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2001,145（4）:546⁃553. DOI: 10.1046/j.1365⁃2133.2001.04411.x.
［41］	Burden AD, Choon SE, Gottlieb AB, et al. Clinical disease measures in generalized pustular psoriasis［J］. Am J Clin Dermatol, 2022,23（Suppl 1）:39⁃50. DOI: 10.1007/s40257⁃021⁃00653⁃0.
［42］	Ibbotson SH. A Perspective on the use of NB⁃UVB phototherapy vs. PUVA photochemotherapy［J］. Front Med （Lausanne）, 2018,5:184. DOI: 10.3389/fmed.2018.00184.
［43］	Zhang P, Wu MX. A clinical review of phototherapy for psoriasis［J］. Lasers Med Sci, 2018,33（1）:173⁃180. DOI: 10.1007/s10103⁃017⁃2360⁃1.
［44］	Goldberg DJ, Chwalek J, Hussain M. 308⁃nm Excimer laser treatment of palmoplantar psoriasis［J］. J Cosmet Laser Ther, 2011,13（2）:47⁃49. DOI: 10.3109/14764172.2011.564769.
［45］	Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2012,67（2）:279⁃288. DOI: 10.1016/j.jaad.2011.01.032.
［46］	Leong HF, Wang WH, Peng F. Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review［J］. Postepy Dermatol Alergol, 2024,41（3）:262⁃269. DOI: 10.5114/ada.2024.141128.
［47］	Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（3）:309⁃316. DOI: 10.1001/jamadermatol. 2017.5937.
［48］	Terui T, Okubo Y, Kobayashi S, et al. Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo⁃controlled study［J］. Am J Clin Dermatol, 2023,24（5）:837⁃847. DOI: 10.1007/s40257⁃023⁃00788⁃2.
［49］	Okubo Y, Kobayashi S, Murakami M, et al. Efficacy and safety of brodalumab, an anti⁃interleukin⁃17 receptor a monoclonal antibody, for palmoplantar pustulosis: 16⁃week results of a randomized clinical trial［J］. Am J Clin Dermatol, 2024,25（5）:837⁃847. DOI: 10.1007/s40257⁃024⁃00876⁃x.
［50］	王娜, 杨青. 阿普米司特治疗掌跖脓疱病一例［J］. 中国麻风皮肤病杂志, 2024,40（8）:565⁃567. DOI: 10.12144/zgmfskin 202408565.
［51］	De Luca DA, Papara C, Hawro T, et al. Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis［J］. J Dermatolog Treat, 2024,35（1）:2399220. DOI: 10.1080/09546634.2024.2399220.
［52］	Heidemeyer K, May Lee M, Cazzaniga S, et al. Palmoplantar pustulosis: a systematic review of risk factors and therapies［J］. Psoriasis （Auckl）, 2023,13:33⁃58. DOI: 10.2147/PTT.S400402.
［53］	Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options［J］. Int J Dermatol, 2011,50（10）:1195⁃1211. DOI: 10.1111/j.1365⁃4632.2011. 04993.x.
［54］	Descos M, Girard C, Girod M, et al. Acrodermatitis continua of Hallopeau successfully treated with spesolimab［J］. Ann Dermatol Venereol, 2025,152（2）:103347. DOI: 10.1016/j.annder.2025.103347.
［55］	He Y, Xiong J, Zhang M, et al. Rapid improvement in refractory acrodermatitis continua of Hallopeau with spesolimab injection［J］. Clin Exp Dermatol, 2025,50（3）:668⁃669. DOI: 10.1093/ced/llae443.
［56］	Morita A, Okubo Y, Imafuku S, et al. Spesolimab, the first⁃in⁃class anti⁃IL⁃36R antibody: from bench to clinic［J］. J Dermatol, 2024,51（11）:1379⁃1391. DOI: 10.1111/1346⁃8138.17449.
［57］	Elias M, Zhao S, Le HT, et al. IL⁃36 in chronic inflammation and fibrosis ⁃ bridging the gap?［J］. J Clin Invest, 2021,131（2）DOI: 10.1172/JCI144336.
［58］	Boehringer Ingelheim International GmbH. 佩索利单抗注射液说明书［Z］. 上海: 勃林格殷格翰（中国）投资有限公司, 2025.
［59］	Boehringer Ingelheim International GmbH. 佩索利单抗注射液(皮下注射）说明书［Z］. 上海: 勃林格殷格翰（中国）投资有限公司, 2025.
［60］	Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta⁃analysis［J］. Dermatol Ther （Heidelb）, 2023,13（2）:437⁃451. DOI: 10.1007/s13555⁃022⁃00877⁃w.
［61］	Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis［J］. Expert Opin Drug Saf, 2020,19（8）:969⁃980. DOI: 10.1080/14740338.2020.1785427.
［62］	Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin⁃1⁃receptor antagonist Anakinra: lack of correlation with IL1RN mutations［J］. Ann Intern Med, 2010,153（1）:66⁃67. DOI: 10.7326/0003⁃4819⁃153⁃1⁃201007060⁃00030.
［63］	Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real⁃life experience［J］. Ther Adv Chronic Dis, 2018,9（8）:147⁃158. DOI: 10.1177/2040622318772705.
［64］	Kurizky PS, Ferreira Cde C, Nogueira LS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding［J］. An Bras Dermatol, 2015,90（3）:367⁃375. DOI: 10.1590/abd1806⁃4841.20153113.
［65］	Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients［J］. Joint Bone Spine, 2016,83（3）:341⁃343. DOI: 10.1016/j.jbspin.2015.07.004.
［66］	Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor⁃alpha inhibitors during pregnancy among women who delivered live born infants［J］. Pharmacoepidemiol Drug Saf, 2019,28（3）:296⁃304. DOI: 10.1002/pds.4695.
［67］	Zhang J, Xia P, Wan L, et al. Generalized pustular psoriasis of pregnancy successfully treated with secukinumab［J］. Indian J Dermatol Venereol Leprol, 2023,89（6）:886⁃888. DOI: 10. 25259/IJDVL_1060_2022.
［68］	Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab［J］. J Dermatol, 2016,43（12）:1439⁃1440. DOI: 10.1111/1346⁃8138.13429.
［69］	Babuna Kobaner G, Polat Ekinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case［J］. Dermatol Ther, 2020,33（4）:e13571. DOI: 10.1111/dth.13571.
［70］	Navarini AA, Pagotto A, Langford B, et al. Mortality, prevalence, comorbidity, and flare patterns in generalised pustular psoriasis: a comprehensive literature review［J］. Eur J Dermatol, 2025,35（6）:459⁃470. DOI: 10.1684/ejd.2025.4998.
［71］	Bachelez H. Pustular Psoriasis: the dawn of a new era［J］. Acta Derm Venereol, 2020,100（3）:adv00034. DOI: 10.2340/00015 555⁃3388.
［72］	Wang Q, Liu W, Zhang L. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China［J］. An Bras Dermatol, 2017,92（3）:319⁃322. DOI: 10.1590/abd1806⁃4841. 20175536.
［73］	Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis⁃⁃most common form of pustular psoriasis in children: report of three cases and review of the literature［J］. Pediatr Dermatol, 2002,19（1）:19⁃25. DOI: 10.1046/j.1525⁃1470.2002. 00026.x.
［74］	Kromer C, Loewe E, Schaarschmidt ML, et al. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients［J］. J Dermatol, 2020,47（9）:989⁃997. DOI: 10.1111/1346⁃8138.15466.

[1]	Li Yanhong, Jiang Kun, Wu Zhuoxuan, Zhang Jianlan, Fang Meizhen, Liu Shuting, Wang Linlin, Hu Lei, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Analysis of 18 cases of cutaneous adverse reactions associated with programmed death-1 inhibitors [J]. Chinese Journal of Dermatology, 2026, 59(8): 783-787.
[2]	Expert Group on the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （ edition）”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 728-737.
[3]	Chinese Society of Dermatology, China Dermatologist Association. Chinese guideline for the diagnosis and treatment of cutaneous squamous cell carcinoma （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 703-716.
[4]	Shi Rongcan¹, ², Yu Zengyang², ³, Luo Qingqiong², Ma Rui¹, ², Jiang Xingyu¹, ², Wang Yuanyuan¹, ², Cai Jiangluyi¹, ², Shi Yuling¹, ². Palmitoyl-proteomic profiles of psoriatic lesions and their role in inflammatory responses: a preliminary study [J]. Chinese Journal of Dermatology, 2026, 59(8): 738-749.
[5]	He Qing, Zhang Tao, Wang Xiuli, Gao Xinghua, Chen Hongduo, Liu Min, Qi Ruiqun. Biomarkers associated with malignant progression of actinic keratosis [J]. Chinese Journal of Dermatology, 2026, 59(7): 687-690.
[6]	Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases [J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674.
[7]	Wang Linlin, Cao Lijuan, Chen Liuqing, Li Dongsheng, Hu Yanyan. Efficacy and safety of hemoporfin-mediated photodynamic therapy for port-wine stains on the extremities: a retrospective analysis [J]. Chinese Journal of Dermatology, 2026, 59(7): 637-644.
[8]	Yuwen Tianyi¹, Zhou Zizhen¹, Tian Jingyu¹, Chen Sihan², Li Min², Zhang Fengyuan¹, Gu Heng, ², Chen Xu, ². Expression of the glutaminase 1/ammonia metabolism axis in keratinocytes in ultraviolet B-induced acute skin injury and psoriatic skin inflammation [J]. Chinese Journal of Dermatology, 2026, 59(7): 654-661.
[9]	Zhang Guolong, Zhao Zijun. Aminolevulinic acid-based photodynamic therapy for cutaneous squamous cell carcinoma: current status, challenges, and perspectives [J]. Chinese Journal of Dermatology, 2026, 59(7): 626-631.
[10]	Hu Yu, Lu Yan, Chen Kun, Gu Heng. Standardization, precision, and full-cycle management: interpretation of Specifications for the Management of Vitiligo Patients Undergoing Home Phototherapy [J]. Chinese Journal of Dermatology, 2026, 59(7): 632-636.
[11]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline for the clinical application of narrowband ultraviolet B phototherapy in dermatology （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 595-610.
[12]	Photodynamic Therapy Research Cooperative Group, Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology & Photodynamic Therapy, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Guideline for the clinical application of aminolevulinic acid-based photodynamic therapy in the treatment of condyloma acuminatum （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 611-618.
[13]	Tian Jing, Song Zhiqiang. Application of tape stripping to the detection of biomarkers in atopic dermatitis [J]. Chinese Journal of Dermatology, 2026, 59(6): 578-581.
[14]	Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504.
[15]	Du Xinran, Wang Xinhe, Li Siyu, Chen Moan, Yuan Shaojie, Yan Ran, Cheng Linyan, Guo Wanjun, Wang Yi, Li Fulun. Development and evaluation of a diagnostic scale for atopic dermatitis with the syndrome of wind dryness due to blood deficiency [J]. Chinese Journal of Dermatology, 2026, 59(6): 540-546.

Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［74］

Related Articles 15

Metrics

Comments

Recommended 2